The cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene on 2q33 is associated with autoimmune thyroid diseases (AITDs). Our earlier study in 56 families showed linkage of 2q33 to the presence of thyroid antibodies (TAbs). The goals of this study were to confirm the linkage of the 2q33 region to TAbs, to fine map this region, and study the ICOS gene. We performed a linkage study in an expanded data set of 99 multiplex AITD-TAb families (529 individuals). The highest two-point LOD score of 2.9 was obtained for marker D2S325 on 2q33. To fine map this locus, we genotyped 238 Caucasian AITD patients and 137 controls for five additional markers in the linked locus, which contained the CTLA-4, CD28, and ICOS genes. The A/G singlenucleotide polymorphism at position 49 of CTLA-4 was associated with AITD (P¼0.01, OR¼1.5), while markers inside CD28 and ICOS were not. Functional studies have shown that the G allele was associated with reduced inhibition of T-cell proliferation by CTLA-4. We concluded that: (1) the AITD gene in the 2q33 locus is the CTLA-4 gene and not the CD28 or ICOS genes; and (2) the G allele is associated with decreased function of CTLA-4.
Introduction
The autoimmune thyroid diseases (AITDs), including Graves' disease (GD) and Hashimoto's thyroiditis (HT), are among the most common human autoimmune diseases. The prevalence of GD and HT in the US population is approximately 1%. 1 GD is characterized by the production of thyroid-stimulating antibodies, which leads to hyperthyroidism, whereas HT is characterized by thyroid cell death and hypothyroidism. 2, 3 The pathogenesis of the AITDs is thought to involve a complex interaction between susceptibility genes 4 and environmental modulating factors. 5 This paradigm is based on epidemiologic evidence demonstrating a genetic predisposition to the AITDs, including: (1) clustering in families giving a sibling risk ratio (l s ) between 5.9 5 and 410 5, 6 ; (2) a high concordance rate in monozygotic twins compared to dizygotic twins 7 ; and (3) the presence of thyroid autoantibodies, which are markers of subclinical AITD, in up to 50% of siblings of patients with AITD. 8 There have been several reports demonstrating an association between the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) gene and the AITDs 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] ( Table 1) . The association between GD and a CTLA-4 3 0 untranslated region (3 0 UTR) microsatellite (AT repeat) and an A/G single-nucleotide polymorphism (SNP) at position 49 in the CTLA-4 leader peptide (A/G 49 ) has been consistent across populations of different ethnic backgrounds, such as Caucasians, 6, 9, 10, [14] [15] [16] [17] Chinese, 11 Japanese, 13, 22 and Koreans. 23 The association of CTLA-4 and GD has also been confirmed in a family-based study using transmission disequilibrium test (TDT) analysis. 16 In contrast, association studies using a C/T SNP in the promotor of CTLA-4 at position -318 (C/T À318 ) were less consistent with some showing association 25 and others not. 24 CTLA-4 was also reported to be associated with HT in various populations including Caucasians 10, 20 and Japanese, 13 although some studies did not find this. 19, 23, 24 Vaidya et al 26 reported linkage to the CTLA-4 gene region on chromosome 2q33 in families with GD using nonparametric linkage analysis. The linkage became stronger when families with AITD, rather than just GD, were included in the study, 26 demonstrating that CTLA-4 most likely conferred general susceptibility to thyroid autoimmunity and not to a specific AITD phenotype. 27 In keeping with the view that the CTLA-4 gene predisposes to thyroid autoimmunity rather than to one specific disease, we found a strong linkage between the CTLA-4 gene region and the presence of thyroid autoantibodies (TAbs). 28 Since the CTLA-4 gene region on chromosome 2q33 also contains the CD28 and ICOS genes, 29 it was unclear whether the CTLA-4 gene itself or another immuneregulatory gene in linkage disequilibrium with CTLA-4 was involved in the genetic susceptibility to AITD. This 2q33 gene should lie within a genomic region of o1 centimorgan (cM) and most likely within a few hundred kilobases of the associated CTLA-4 markers, based on the degree of linkage disequilibrium observed in the human genome. 30, 31 Therefore, since CD28 and ICOS are located within 50-150 kb from CTLA-4, 29 they may be the genes responsible for conferring susceptibility to autoimmune diseases. Our earlier study using 56 AITD families suggested that CTLA-4 and not CD28 was the AITD susceptibility gene in this region. 28 Recently, the entire region containing the CD28, CTLA-4, and ICOS genes has been sequenced, and several new polymorphisms identified. 29 In this study, we used these newly identified polymorphisms to fine map the CTLA-4 gene region on 2q33 and to examine directly the CD28 and ICOS genes.
Results
Characteristics of the study sample Table 2 shows the clinical characteristics of the 99 families studied. In all, 32 (32%) had only GD-affected members, 30 (30%) had only HT-affected members, and 37 (37%) had both GD-and HT-affected first-degree relatives. Of the 242 affected individuals, 200 (83%) were females, and the affected female:male (F:M) ratio (5:1) was in accordance with that reported in the literature. 32 Of the clinically and biochemically unaffected family members, 35% had thyroid antibodies, similar to the incidence reported in previous studies. 8, 33 Screening chromosome 2 for TAb loci For mapping the thyroid antibody susceptibility genes, TAb-positive individuals with or without GD/HT were considered affected. Linkage analysis gave positive LOD scores on 2q33, with a two-point maximum LOD score (MLS) of 2.9 for marker D2S325 (208.5 cM, dominant model, 70% penetrance, recombination fraction (y) of 0.2). When we defined only GD patients as affected, the two-point MLS was 1.0. When we defined only HT patients as affected, the two-point MLS was 0.8. Thus, the LOD score maximized when considering TAbpositive individuals as affected, and was lower when they were considered unaffected.
Fine mapping of the TAb susceptibility locus using multipoint linkage analysis To fine map the TAb susceptibility locus, we performed a multipoint analysis using densely spaced markers at 2q33. We generated a genetic map for the 2q33 region using 10 markers, with sex-averaged distances between markers (in cM) as follows: D2S117-1.0-D2S316-1.0- GD, Graves' disease; GO, Graves' ophthalmopathy; HT, Hashimoto's thyroiditis.
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. This order and distances in cM were obtained from the Genethon maps, 34 and were confirmed in our data set.
Multipoint linkage analysis localized the TAb susceptibility locus on chromosome 2q33 to within an approximate interval of 2.5 cM between markers D2S155 and D2S325. Multipoint LOD scores throughout this interval were 42.0 when assuming heterogeneity in the analysis.
The maximum heterogeneity multipoint LOD score was 3.1, obtained near marker D2S154 (a¼0.28, Figure 1 , Table 3 , bold).
Additional fine mapping of the TAb locus using association analyses We genotyped the CTLA-4 A/G 49 SNP, the CD28 IVS3 þ 17C/T SNP, and three microsatellite markers in the region surrounding CTLA-4 and ICOS genes. Figure 2 shows the relative positions of the five markers used to analyze the human 2q33 costimulatory gene region. We compared 238 Caucasian AITD patients (99 of them probands from our families) to 137 age-and sexmatched Caucasian controls ( Table 4 ). The analysis showed a statistically significant association of AITD with the CTLA-4 A/G 49 SNP (P¼0.01, RR¼1.5) and SARA 31 (P¼0.05, RR¼1.4) ( Table 4 ). The remaining markers, CD28 IVS3 þ 17C/T SNP, D2S307, and ICOS (GT)n, showed no statistically significant association with AITD (Table 4) . We grouped alleles with o10% frequency together for this analysis. AITD, autoimmune thyroid disease; OR, odds ratio; NS, not significant.
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Association analyses using probands from families linked with the TAb locus (n¼35)
Since we demonstrated evidence for genetic heterogeneity in our families (Table 3) , we performed an association study for markers on 2q33 using only the probands from the families linked with the TAb locus (n¼35). The families were partitioned into linked and unlinked, as previously described. 28 The analysis showed that 51.4% of probands from the linked families had the G allele of CTLA-4 A/G 49 SNP versus 32.5% of the controls (P¼0.003, RR¼2.2; Table 5 ). All other markers on 2q33 did not show an association in the probands from the linked families. Thus, the association of AITD with CTLA-4 was stronger in probands from the linked families.
Effect of CTLA-4 A/G 49 SNP on the inhibition of T-cell proliferation by CTLA-4 To determine whether the A/G SNP influenced CTLA-4 function, we compared T-cell proliferation between the different genotype groups under conditions of CTLA-4/ B7 blockade by anti-CTLA-4 mAb. We calculated the percentage of increased proliferation after CTLA-4 blockade using the following formula: % increased proliferation¼(1À((T-cell proliferation with anti-CD3 þ anti-CTLA-4 mAb (CPM))/(T-cell proliferation with anti-CD3 (CPM)))) Â 100 (%). When the results were analyzed based on the CTLA-4 A/G 49 SNP genotyping, proliferation of T cells from subjects with the AA genotypes was increased by 46% following CTLA-4 blockade, whereas proliferation of cells from GGexpressing subjects was increased by 4% (P¼0.04) (Figure 3) . Thus, there was a borderline significant difference between the AA and the GG groups. However, there was no difference between the AA and the (AG þ GG) groups (P¼0.16).
Discussion
Autoantibodies to Tg and TPO are present in almost all patients with AITDs, and in approximately 50% of family members. This study confirmed our previous results in a smaller data set, showing strong evidence that the CTLA-4 gene region contains a major TAb susceptibility gene. Furthermore, our fine-mapping analysis demonstrated that the CTLA-4 gene itself, and not CD28 or ICOS, is the Genetic and functional studies of CTLA-4 with AITD Y Ban et al AITD susceptibility gene. Since, in our earlier study, the ICOS gene was not tested, we have tested the ICOS gene directly using a microsatellite inside intron 4. Our results clearly demonstrated that ICOS was not the TAb susceptibility gene in the 2q33 region. The finding of CTLA-4 as a gene for thyroid autoantibody secretion supports the suggestion that the production of thyroid antibodies is an early event in the development of clinical disease. In addition, the fact that CTLA-4 was linked with TAbs and not with any specific AITD phenotype supports the notion that CTLA-4 is a general autoimmunity susceptibility gene. 27 Indeed, CTLA-4 has been shown to be associated with other autoimmune diseases. 14, 18 Genetic susceptibility to the production of thyroid antibodies was first suggested by Hall et al. 35 Their studies of first-degree relatives of probands with AITDs indicated proportions of affected relatives similar to the theoretical expectation for dominant inheritance. More recent family studies have shown that up to 50% of the siblings of AITD patients were TAb positive, 8, 32 in contrast to a TAb population prevalence of 7-15%. 36 The genetic susceptibility to the production of thyroid antibodies was further supported by several segregation analyses in families with thyroid antibodies that suggested a Mendelian dominant pattern of inheritance. [37] [38] [39] Indeed, our results have shown CTLA-4 to be linked with TAbs in a dominant inheritance pattern. In addition, it was recently found that recognition of particular TPO epitopes within the autoantibody immunodominant region may be transmitted within families. 40 The chromosomal region giving positive LOD scores contained three important immune-regulatory genes: the CTLA-4, CD28, and ICOS genes. CD28 and CTLA-4 are important regulators of T-cell activation by antigenpresenting cells. 41 CD28 enhances T-cell functions essential for effective antigen-specific immune responses, whereas CTLA-4 counterbalances the CD28-mediated signals and thus prevents overstimulation of the lymphoid system. 41 A newer member of this family of costimulatory receptors, 'inducible costimulator' (ICOS), was identified by Hutloff et al. 42 Unlike the constitutively expressed CD28, ICOS is induced on the T-cell surface and functions to predominantly upregulate interleukin (IL)-4 as opposed to IL-2. 43 Recent sequence analysis demonstrated that the CD28, CTLA-4, and ICOS genes locate telomerically in this order in B230-kb region on chromosome 2q33. 29 However, there have been no studies on the genetic contribution of the ICOS gene to the development of AITD. Our data do not support CD28 and ICOS as AITD susceptibility genes on 2q33, and showed that CTLA-4 is the only susceptibility gene in this region. The CTLA-4 gene and not CD28 or ICOS genes showed a clear association with AITD (Table 4) , and this association became stronger in the families that showed positive evidence of linkage (Table 5) .
Since the G allele of the CTLA-4 A/G 49 SNP was associated with AITD, we examined its effect on the function of CTLA-4. We found that the presence of the GG genotype resulted in less increase in T-cell proliferation upon blocking CTLA-4 when compared to the AA genotype. Similarly, other investigators have examined the effects of the A and G alleles of the CTLA-4 A/G 49 SNP on the inhibitory function of CTLA-4. [44] [45] [46] The GG genotype was found to be associated with reduced inhibitory function of CTLA-4 on T-cell proliferation after stimulation with an allogeneic cell line, and with decreased CTLA-4 surface expression. [44] [45] [46] This could imply that the A and G alleles of the CTLA-4 leader sequence influenced its function and/or expression. However, a recent study showed that the G allele does not affect the function and/or expression of CTLA-4 directly, and another polymorphism in linkage disequilibrium may be responsible for the association with AITD. 47 Xu et al 47 have examined the effects of the CTLA-4 A/G 49 SNP using an in vitro assay by transfecting T-cell lines lacking CTLA-4 with CTLA-4 cDNA carrying the A or the G allele. There was no difference in the expression of CTLA-4 and in the inhibitory function of CTLA-4 when T cells were transfected with CTLA-4 cDNA carrying the G or the A allele, suggesting that the A and G alleles of the CTLA-4 A/G 49 SNP did not directly influence its function. 47 Thus, our results and previous results showing decreased function and/or expression of CTLA-4 in individuals carrying the G allele [44] [45] [46] must reflect the effects of another CTLA-4 polymorphism that is in linkage disequilibrium with the A/G 49 SNP. Therefore, the A/G 49 SNP can be used as a surrogate marker until the causative polymorphism is identified. Indeed, preliminary data in myasthenia gravis showed that the (AT)n microsatellite at the 3 0 UTR of the CTLA-4 gene influenced the half-life of the CTLA-4 mRNA, 48, 49 and contributed to decreased mRNA stability. 50 This could provide an attractive explanation for the association between the short alleles of the (AT)n microsatellite and AITD, as well as other autoimmune diseases. Other studies have reported that individuals carrying thymidine at position -318 of the CTLA-4 promoter showed significantly increased expression both of cell-surface CTLA-4 after cellular stimulation and CTLA-4 mRNA in nonstimulated cells. 45 In conclusion, we confirmed strong evidence for a susceptibility gene for thyroid autoimmunity on chromosome 2q33 in our expanded data set. This gene was mapped to within 2.5 cM of the CTLA-4 gene cluster, and our association studies confirmed that the CTLA-4 gene was the TAb susceptibility gene in this region. Our functional study of the CTLA-4 A/G 49 SNP showed that the presence of the G allele appears to be associated with decreased function of CTLA-4, and this could lead to increased immune responsiveness and susceptibility to develop AITD.
Materials and methods
Ascertainment of the study families
The project was approved by our institutional review board. In all, 99 Caucasian AITD families (529 individuals) were used for our linkage analysis (51 from North America, 29 from Italy, 10 from Israel, and nine from the UK). All families enrolled in the study were multiplex for AITD (more than one affected) and multigenerational. Families were ascertained through a patient with AITD, who confirmed having at least one other first-degree relative with AITD. While as many relatives as possible were recruited from each family, the minimum requirement for participation in the study was a family consisting of four first-degree relatives (including the proband) from two generations. On the average, our families had 5.3 members.
Ascertainment of the sporadic AITD patients and controls A total of 139 Caucasian AITD patients without family history of AITD (124 with GD and 15 with HT) were included in the case-control association studies together with the probands from the AITD families (n¼99, 60 with GD, and 39 with HT). In all, 137 age-and sex-matched Caucasian individuals were used as controls in our association studies.
Clinical assessment
For the linkage study, all patients with GD, HT, or with thyroid autoantibodies (antithyroglobulin (Tg) or antithyroid peroxidase (TPO) antibodies) alone without clinical disease were considered affected. The diagnosis of GD was determined on the basis of documented clinical and biochemical evidence of past or present hyperthyroidism requiring treatment (antithyroid medications, radioactive iodine or surgery), plus the presence of at least one of the following: positive TSH-receptor antibodies, exophthalmos, and/or a diffusely increased 131 I uptake by the thyroid gland. HT was diagnosed by documented clinical and biochemical hypothyroidism requiring thyroid hormone replacement and the presence of anti-TPO, with or without anti-Tg antibodies, with or without goiter. Anti-Tg and anti-TPO antibodies were measured by specific radioimmunoassay (Kronus, Boise, ID, USA). For all subjects, the phenotype was determined with the clinician blinded to the individual's genotype. All controls were confirmed to be clinically and biochemically euthyroid, and were negative for thyroid antibodies.
PCR amplification of microsatellite markers DNA was extracted from whole blood using the Puregene kit (Gentra Systems, Minneapolis, MN, USA). For the screening of chromosome 2, we used 13 microsatellite markers from the ABI panel (Perkin-Elmer ABI, Foster City, CA, USA). In addition, oligonucleotides for amplification of the microsatellites used for fine mapping were designed according to published sequences. 29 For fine mapping the chromosome 2q33 region, microsatellite markers were selected using the known sequence of the human 2q33 costimulatory receptor region ( Figure  2) . 29 PCRs were performed in 15-ml reaction volumes as previously described. 28 The PCR products were diluted 1:20 in ddH 2 O and pooled. A volume of 2 ml of the pooled products were mixed with 0.5 ml of the internal size standard and 10 ml deionized formamide, denatured, and separated using an ABI 310 genetic analyzer (PE Applied Biosystems). Allele calling was performed using Genotyper TM 2.0 software (PE Applied Biosystems). The marker data were then automatically exported to our database (Oracle TM database), where they were integrated with the already-existing phenotype information and prepared for linkage and association analysis.
SNP genotyping
The CTLA-4 A/G 49 SNP was typed by a fluorescentlabeled restriction fragment-length polymorphism (RFLP) method, as previously described. 28 The CD28 C/ T SNP at position 17 of intron 3 (CD28 IVS3 þ 17C/T SNP) was typed by a similar fluorescent-labeled RFLP method, as previously described. 28 Linkage analysis Linkage analysis was performed using maximum-likelihood-based (LOD score) methods of linkage analysis. Two-point: LOD scores were computed using LIPED software, 51 assuming dominant inheritance and 70% penetrance based on our previous results. 28 We considered a LOD score 41.9 as suggestive evidence for linkage, 52 and a LOD score 43.3 as evidence for significant linkage. 52 Multipoint LOD scores were computed by the GeneHunter program 53 using all the markers on chromosome 2. Multipoint linkage analysis yields the maximum marker information for the area of interest. For the multipoint analysis, we set the inheritance parameters to the same values as for the two-point analysis (70% penetrance, dominant model). Marker placement and distances for the multipoint analysis were obtained from the Genethon maps. 34 
Association analysis
Case-control association analyses were performed using the w 2 and Fisher's exact tests. Po0.05 was considered significant. We grouped alleles with o10% frequency together for this analysis.
T-cell proliferation assays
Functional studies of CTLA-4 A/G 49 SNP were performed in 17 healthy individuals (age range 30-62 years). Mononuclear cells were isolated from heparinized whole blood by density-gradient centrifugation over FicollHypaque (Pharmacia, Piscataway, NJ, USA). Cells were cultured in RPMI 1640 medium supplemented with fetal calf serum (FCS; 10%), L-glutamine (2 mM), and penicillin-streptomycin (100 U/ml, 100 mg/ml) (Gibco, Grand Island, NY, USA). Cultures of cells were split into three groups at a concentration of 5 Â 10 4 cell/ml: the first was cultured in medium alone, the second was stimulated with 10 mg/ml plate-immobilized anti-CD3 (OKT3; Ortho Biotech Inc., Raritan, NJ, USA), and the third was stimulated with plate-immobilized anti-CD3 in the presence of 250 ng/ml of antibody to CTLA-4 (antihuman CTLA-4 mAb; PharMingen, San Diego, CA, USA). After 48 h, the cells were pulsed with 1 mCi/well of [
